Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, Cai-Hong, Boggon, Titus J., Li, Yiqun, Woo, Michele S., Greulich, Heidi, Meyerson, Matthew, Eck, Michael J.·2007·Cancer Cell
DOI 10.1016/j.ccr.2006.12.017

Cited by (1,000)

Items 201–300 of 1,000

  1. Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform
    Connie S. Lebakken, Steven M. Riddle, Upinder Pal Singh, William J. Frazee, Hildegard C. Eliason, Yi Qin Gao, Laurie J. Reichling, Bryan D. Marks, Kurt W. Vogel · 2009 · SLAS DISCOVERY
  2. Computational Modeling of Allosteric Communication Reveals Organizing Principles of Mutation-Induced Signaling in ABL and EGFR Kinases
    Anshuman Dixit, Gennady M. Verkhivker · 2011 · PLoS Computational Biology
  3. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
    Alicia J. Angelbello, Jonathan L. Chen, Jessica L. Childs‐Disney, Peiyuan Zhang, Zi-Fu Wang, Matthew David Disney · 2018 · Chemical Reviews
  4. Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
    Yoojung Kwon, Mi-Sun Kim, Hyun Suk Jung, Youngmi Kim, Dooil Jeoung · 2019 · Cancers
  5. Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models
    Mi Young Cha, Kwang‐Ok Lee, Mi‐Ra Kim, Ji Yeon Song, Kyu Hang Lee, Jongmin Park, Yun Jung Chae, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee et al. · 2011 · International Journal of Cancer
  6. EGFR Trafficking in Physiology and Cancer
    Giusi Caldieri, Maria Grazia Malabarba, Pier Paolo Di Fiore, Sara Sigismund · 2018 · Progress in molecular and subcellular biology
  7. Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells
    Fabrizio Capuani, Alexia Conte, Elisabetta Argenzio, Luca Marchetti, Corrado Priami, Simona Polo, Pier Paolo Di Fiore, Sara Sigismund, Andrea Ciliberto · 2015 · Nature Communications
  8. Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases
    Nicholas Endres, Tiago F. Barros, Aaron J. Cantor, John Kuriyan · 2014 · Trends in Biochemical Sciences
  9. Regulation of Target Protein Knockdown and Labeling Using Ligand-Directed Ru(bpy)3 Photocatalyst
    Shinichi Sato, Kohei Morita, Hiroyuki Nakamura · 2014 · Bioconjugate Chemistry
  10. Cell and Molecular Biology of Epidermal Growth Factor Receptor
    Brian P. Ceresa, Joanne L. Peterson · 2014 · International review of cytology
  11. Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins
    Katharine A. White, Diego Garrido Ruiz, Zachary A. Szpiech, Nicolas B. Strauli, Ryan D. Hernandez, Matthew P. Jacobson, Diane L. Barber · 2017 · Science Signaling
  12. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR
    Trent E. Balius, Robert C. Rizzo · 2009 · Biochemistry
  13. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
    Nina Shaban, Dmitri Kamashev, Aleksandra Emelianova, Anton A. Buzdin · 2023 · Cells
  14. The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
    Ron Bose, Xuewu Zhang · 2008 · Experimental Cell Research
  15. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
    Giuseppe Bronte, Christian Diego Rolfo, Elisa Giovannetti, Giuseppe Cicero, Patrick Pauwels, Francesco Passiglia, Marta Castiglia, Sérgio Rizzo, Francesca Lo Vullo, Eugenio Fiorentino et al. · 2013 · Critical Reviews in Oncology/Hematology
  16. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations
    Issan Yee San Tam, Elaine Lai‐Han Leung, Vicky Pui‐Chi Tin, Daniel Tsin-Tien Chua, Alan Dart‐Loon Sihoe, Lik‐Cheung Cheng, Lap-Ping Chung, Maria Pik Wong · 2009 · Molecular Cancer Therapeutics
  17. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro
    Jin Keun Chang, Hongyu Ren, Mingxia Zhao, Chong Yan, Wenwen Zhao, Yong He, Yunling Zhao, Huabei Zhang, Chuanmin Qi · 2017 · European Journal of Medicinal Chemistry
  18. TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
    Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka et al. · 2019 · Molecular Cancer Research
  19. Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer
    Lixia Ju, Caicun Zhou, Wěi Li, Linghua Yan · 2010 · Journal of Cellular Biochemistry
  20. Current Approaches in NSCLC Targeting K-RAS and EGFR
    Veronica Aran, Jasminka Omerović · 2019 · International Journal of Molecular Sciences
  21. KinaseMD: kinase mutations and drug response database
    Ruifeng Hu, Haodong Xu, Peilin Jia, Zhongming Zhao · 2020 · Nucleic Acids Research
  22. Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
    Ratika Krishnamurty, Dustin J. Maly · 2010 · ACS Chemical Biology
  23. Biomarkers in Lung Adenocarcinoma: A Decade of Progress
    Lynette Marie Sholl · 2014 · Archives of Pathology & Laboratory Medicine
  24. Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
    Chung, Kuei-Pin, Wu, Shang-Gin, Wu, Jenn-Yu, Yang, James Chih-Hsin, Yu, Chong-Jen, Wei, Pin-Fei, Shih, Jin-Yuan, Yang, Pan-Chyr · 2012 · Clinical Cancer Research
  25. Weighted Equation and Rules—A Novel Concept for Evaluating Protein-Ligand Interaction
    Calvin Yu‐Chian Chen · 2009 · Journal of Biomolecular Structure and Dynamics
  26. Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma
    Janet Wangari‐Talbot, Elizabeth A. Hopper-Borge · 2013 · Journal of cancer research updates
  27. EGF Receptor Exposed to Oxidative Stress Acquires Abnormal Phosphorylation and Aberrant Activated Conformation That Impairs Canonical Dimerization
    Simone Filosto, Elaine M. Khan, Emiliana Tognon, Cathleen R. Becker, Majid Ashfaq, Tommer Ravid, Tzipora Goldkorn · 2011 · PLoS ONE
  28. EGFR Signaling in Lung Fibrosis
    Fabian Schramm, Liliana Schaefer, Małgorzata Wygrecka · 2022 · Cells
  29. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors
    Sandra N. Milik, Deena S. Lasheen, Rabah A.T. Serya, Khaled A. M. Abouzid · 2017 · European Journal of Medicinal Chemistry
  30. Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies
    Zhiwei Yu, Titus J. Boggon, Susumu S. Kobayashi, Cheng Jin, Patrick C. Ma, Afshin Dowlati, Jeffrey A. Kern, Daniel Geoffrey Tenen, Balázs Halmos · 2007 · Cancer Research
  31. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
    Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, Hamdy Mohamed Abdel-Rahman, Mohamed Abdel‐Aziz · 2023 · RSC Advances
  32. EGF Transregulates Opioid Receptors through EGFR-mediated GRK2 Phosphorylation and Activation
    Yuejun Chen, Hui Long, Ziyan Wu, Xi Jiang, Lan Ma · 2008 · Molecular Biology of the Cell
  33. EGFR inhibition in the treatment of non‐small cell lung cancer
    David E. Gerber · 2008 · Drug Development Research
  34. Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations
    Anshuman Dixit, Gennady M. Verkhivker · 2009 · PLoS Computational Biology
  35. A Structural View on Medicinal Chemistry Strategies against Drug Resistance
    Stefano Agnello, Michael Brand, Mathieu F. Chellat, Silvia Gazzola, Rainer Riedl · 2018 · Angewandte Chemie International Edition
  36. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
    Alexandru Șandor, Ioana A. Ionuţ, Gabriel Marc, Ilioara Oniga, Dan Tudor Eniu, Ovidiu Oniga · 2023 · Pharmaceuticals
  37. Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
    Tona M. Gilmer, LouAnn Cable, Krystal J. Alligood, David W. Rusnak, Glenn M. Spehar, Kathleen T. Gallagher, Ermias Woldu, H. Luke Carter, Anne T. Truesdale, Lisa M. Shewchuk et al. · 2008 · Cancer Research
  38. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors
    Bin Zhang, Zhikun Liu, Shengjin Xia, Qingqing Liu, Shao-Hua Gou · 2021 · European Journal of Medicinal Chemistry
  39. Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant
    Wei Zhou, Xiaofeng Liu, Zhengchao Tu, Lianwen Zhang, Xin Ku, Fang Bai, Zhenjiang Zhao, Yufang F. Xu, Ke Ding, Honglin Li · 2013 · Journal of Medicinal Chemistry
  40. Genetically informed lung cancer medicine
    William J. Pao, Anthony John Iafrate, Zengliu Su · 2010 · The Journal of Pathology
  41. The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
    Marlon Roberto Schneider, Yosef Yarden · 2015 · Oncogene
  42. Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors
    David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan Laufer, Michael J. Eck · 2020 · Journal of Medicinal Chemistry
  43. Targeting Gatekeeper Mutations for Kinase Drug Discovery
    Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu · 2022 · Journal of Medicinal Chemistry
  44. Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
    Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura · 2009 · Cancer Research
  45. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
    Xiaoyun Lu, Jeff Bruce Smaill, Ke Ding · 2020 · Journal of Medicinal Chemistry
  46. Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
    Zhenfang Du, Benjamin P. Brown, Soyeon Kim, Donna C. Ferguson, Dean C. Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean‐Nicolas Gallant, Yunkai Zhang, Yingjun Yan et al. · 2021 · Nature Communications
  47. What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements
    Wendy A. Cooper, Sandra A O'Toole, Michael Joseph Boyer, Lisa Glen Horvath, Annabelle M. Mahar · 2011 · Pathology
  48. Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents
    Milan Remko, Andrej Boháč, Lucia Kováčiková · 2011 · Structural Chemistry
  49. Structure-based design of molecular cancer therapeutics
    Rob L. M. van Montfort, Paul Workman · 2009 · Trends in biotechnology
  50. Mechanisms of resistance to EGFR targeted therapies
    Gorjan Hrustanovic, Bianca J. Lee, Trever Grant Bivona · 2013 · Cancer Biology & Therapy
  51. Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations
    Matthew J. Lazzara, Keara M. Lane, Richard Chan, Paul Jasper, Michael B. Yaffe, Peter Karl Sorger, Tyler Jacks, Benjamin G. Neel, Douglas A. Lauffenburger · 2010 · Cancer Research
  52. Structure–activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor
    Steffen Bugge, Svein Jacob Kaspersen, Synne Larsen, Unni Nonstad, Geir Bjørkøy, Eirik Sundby, Bård Helge Hoff · 2014 · European Journal of Medicinal Chemistry
  53. The NADPH Oxidases DUOX1 and NOX2 Play Distinct Roles in Redox Regulation of Epidermal Growth Factor Receptor Signaling
    David E. Heppner, Milena Hristova, Christopher M. Dustin, Karamatullah Danyal, Aida Habibovic, Albert van der Vliet · 2016 · Journal of Biological Chemistry
  54. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations
    Zheng Ruan, Natarajan Kannan · 2018 · Proceedings of the National Academy of Sciences
  55. Somatic Mutations of ErbB4
    Denis Tvorogov, Maria Sundvall, Kari J. Kurppa, Maija Hollmén, Susanna Repo, Mark S. Johnson, Klaus Elenius · 2008 · Journal of Biological Chemistry
  56. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells
    Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, Aoi Kuroda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki et al. · 2015 · Molecular Cancer Therapeutics
  57. Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
  58. Structural and biochemical studies of the PDGFRA kinase domain
    Ling Liang, Xiao-E Yan, Yuxin Yin, Cai‐Hong Yun · 2016 · Biochemical and Biophysical Research Communications
  59. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer
    Hezha O. Rasul, Bakhtyar K. Aziz, Dlzar Dlshad Ghafoor, Arif Kıvrak · 2021 · Journal of Molecular Modeling
  60. Interocular induction of illusory size perception
    Chen Song, Dietrich Samuel Schwarzkopf, Geraint E. Rees · 2011 · BMC Neuroscience
  61. Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
    Johannes M. Heuckmann, Daniel Rauh, Roman Kurt Thomas · 2012 · Journal of Clinical Oncology
  62. Bisphosphonates inactivate human EGFRs to exert antitumor actions
    Tony Yuen, Agnes Stachnik, Jameel Z. Iqbal, Miriam Sgobba, Yogesh K. Gupta, Ping Lü, Graziana Colaianni, Yaoting Ji, Ling-Ling Zhu, Se‐Min Kim et al. · 2014 · Proceedings of the National Academy of Sciences
  63. Physical–chemical principles underlying RTK activation, and their implications for human disease
    Lijuan He, Kalina A. Hristova · 2011 · Biochimica et Biophysica Acta (BBA) - Biomembranes
  64. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Robert Charles Doebele, Ana Belen Oton, Nir Peled, D. Ross Camidge, Paul A. Bunn · 2010 · Lung Cancer
  65. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam Jacob Schoenfeld, Jessica R. Flynn, Christina J. Falcon, Hira A. Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena Alexandra Yu et al. · 2021 · Clinical Cancer Research
  66. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity
    Inderjit Singh Yadav, Prajwal Prabhakarrao Nandekar, Shambhavi Shrivastava, Abhay T. Sangamwar, Ashok Chaudhury, Subhash Mohan Agarwal · 2014 · Gene
  67. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer
    Qiang Zhen, Junfeng Liu, Lina Gao, Jiabao Liu, Renfeng Wang, Weiwei Chu, Yaxiao Zhang, Guoliang Tan, Xiaojian Zhao, Baolei Lv · 2015 · Cytogenetic and Genome Research
  68. Structure guided design and binding analysis of EGFR inhibiting analogues of erlotinib and AEE788 using ensemble docking, molecular dynamics and MM-GBSA
    Vishnu Sharma, Prajwal Prabhakarrao Nandekar, Abhay T. Sangamwar, Horacio Pérez‐Sánchez, Subhash Mohan Agarwal · 2016 · RSC Advances
  69. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
    Tadashi Manabe, Hiroyuki Yasuda, Hideki Terai, Harumi Kagiwada, Junko Hamamoto, Toshiki Ebisudani, Keigo Kobayashi, Keita Masuzawa, Shinnosuke Ikemura, Ichiro Kawada et al. · 2020 · Molecular Cancer Research
  70. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
    Krishna Babu Duggirala, Yujin Lee, Kwangho Lee · 2021 · Biomolecules & Therapeutics
  71. Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
    Jiao Yang, Lijiao Wang, Jingjing Liu, Lei Zhong, Renlin Zheng, Yong Xu, Pan Ji, Chunhui Zhang, Wenjing Wang, Xingdong Lin et al. · 2012 · Journal of Medicinal Chemistry
  72. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Yuri Rukazenkov, Georgina Speake, Gayle B. Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson, Alan J. Swaisland · 2009 · Anti-Cancer Drugs
  73. Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers
    Mahima Mishra, Rubai Ahmed, Deepak Kumar Das, Devlina Das Pramanik, Sandeep Kumar Dash, Arindam Pramanik · 2024 · ACS Biomaterials Science & Engineering
  74. Discovery of 1-Methyl-1 H -imidazole Derivatives as Potent Jak2 Inhibitors
    Qibin Su, Stephanos Ioannidis, Claudio E. Chuaqui, Lynsie Almeida, Marat B. Alimzhanov, Geraldine A. Bebernitz, Kirsten Bell, Michael Block, Tina D. Howard, Shan Wei Huang et al. · 2013 · Journal of Medicinal Chemistry
  75. In Vitro Enzymatic Characterization of Near Full Length EGFR in Activated and Inhibited States
    Chen Qiu, Mary Katherine Tarrant, Tatiana N. Boronina, Patti A. Longo, Jennifer M. Kavran, Robert Norman Cole, Philip A. Cole, Daniel J. Leahy · 2009 · Biochemistry
  76. GARD: A Generally Applicable Replacement for RMSD
    J. Christian Baber, David C. Thompson, Jason B. Cross, Christine C. Humblet · 2009 · Journal of Chemical Information and Modeling
  77. Kinase-mediated quasi-dimers of EGFR
    Erez M. Bublil, Gur Pines, Gargi Surendra Patel, Gilbert O. Fruhwirth, Tony Ng, Yosef Yarden · 2010 · The FASEB Journal
  78. The Energy Landscape Analysis of Cancer Mutations in Protein Kinases
    Anshuman Dixit, Gennady M. Verkhivker · 2011 · PLoS ONE
  79. Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation
    Jan van Noesel, Ward H. van der Ven, Theo A.M. van Os, Peter W.A. Kunst, Jitske Weegenaar, Roy J.A. Reinten, Rama Krishna Kancha, Justus Duyster, Carel J.M. van Noesel · 2013 · Journal of Clinical Oncology
  80. The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment
    Norahayu Othman, Noor Hasima Nagoor · 2014 · BioMed Research International
  81. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
    Pasi Antero Janne, Alice Tsang Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean‐François Martini, Huiping Xu, Leonard Philip James et al. · 2016 · Journal of Thoracic Oncology
  82. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands
    Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias Philipp Müller, Jonas Lategahn, Daniel Rauh · 2020 · ACS Medicinal Chemistry Letters
  83. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
    Byung Min Chung, Manjari Dimri, Manju George, Alagarsamy Lakku Reddi, G Chen, Vimla Band, Hamid Band · 2009 · Oncogene
  84. Investigations of structural, spectral and electronic properties of enrofloxacin and boron complexes via quantum chemical calculation and molecular docking
    Koray Sayın, Ayhan Üngördü · 2019 · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
  85. Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers
    Krister J. Barkovich, Sujatmi Hariono, Adam L. Garske, Jie Zhang, Jimmy A. Blair, Qi‐Wen Fan, Kevan M. Shokat, Theodore P. Nicolaides, William A. Weiss · 2012 · Cancer Discovery
  86. Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Aarif Ahsan · 2015 · Advances in experimental medicine and biology
  87. Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
    Rodrigo Dienstmann, Pablo Martínez, Enriqueta Felip · 2011 · Oncotarget
  88. Spectroscopic studies, DFT calculations, cytotoxicity activity, and docking stimulation of novel metal complexes of Schiff base ligand of isonicotinohydrazide derivative
    Nelly H. Mahmoud, Ghada H. Elsayed, Asmaa Aboelnaga, Asmaa Mahmoud Fahim · 2022 · Applied Organometallic Chemistry
  89. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents
    Kai Liu, Xiang Lu, Hongjia Zhang, Juan Sun, Hai‐Liang Zhu · 2011 · European Journal of Medicinal Chemistry
  90. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines
    Estefanía Carrasco‐García, Miguel Saceda, Silvina Grasso, Lourdes Rocamora‐Reverte, Mariano Conde, Ángeles Gómez‐Martínez, Pilar García-Morales, José A. Ferragut, Isabel Martínez-Lacaci · 2011 · Experimental Cell Research
  91. Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR–Cysteine 797 andN-(4-Anilinoquinazolin-6-yl) Acrylamide
    Luigi Capoferri, Alessio Lodola, Silvia Rivara, Marco Mor · 2015 · Journal of Chemical Information and Modeling
  92. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
    Qi Wang, Julie Anne Zorn, John Kuriyan · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
  93. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Xiaochun Wang, David Goldstein, Philip John Crowe, Jialin Yang · 2016 · OncoTargets and Therapy
  94. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib‐resistant lung cancer growth
    Sung Keun Jung, Mee‐Hyun Lee, Do Young Lim, Sungyoung Lee, Chul‐Ho Jeong, Jong‐Eun Kim, Tae Gyu Lim, Hanyong Chen, Ann M. Bode, Hyong Joo Lee et al. · 2014 · Molecular Carcinogenesis
  95. Constitutive Activation of Epidermal Growth Factor Receptor Promotes Tumorigenesis of Cr(VI)-transformed Cells through Decreased Reactive Oxygen Species and Apoptosis Resistance Development
    Donghern Kim, Jin Dai, Leonard Nsoyori Yenwongfai, Hua Yao, Young‐Ok Son, Lei Wang, Poyil Pratheeshkumar, Kazuya Kondo, Xianglin Shi, Zhuo Zhang · 2014 · Journal of Biological Chemistry
  96. Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
    Chao Ding, Shaopeng Chen, Cunlong Zhang, Guangnan Hu, Wei Zhang, Lulu Li, Yu Chen, Chunyan Tan, Yuyang Jiang · 2016 · Bioorganic & Medicinal Chemistry
  97. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
    Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku · 2017 · Oncotarget
  98. Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors
    Romeo Romagnoli, Filippo Prencipe, Paola Oliva, Stefania Baraldi, Pier Giovanni Baraldi, Santiago Schiaffino‐Ortega, Mariem Chayah, María Kimatrai Salvador, Luisa Carlota Lopez-Cara, Andrea Brancale et al. · 2019 · Journal of Medicinal Chemistry
  99. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
    Mahlet Z. Tamirat, Marika K.A. Koivu, Klaus Elenius, Mark S. Johnson · 2019 · PLoS ONE
  100. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
    Daniel N. do Amaral, Jonas Lategahn, Harold Hilarion Fokoue, Eduardo Miguez Bastos da Silva, Carlos Maurício R. Sant’Anna, Daniel Rauh, Eliezer J. Barreiro, Stefan Laufer, Lı́dia Moreira Lima · 2019 · Scientific Reports